Butantan may resume clinical trials for tetravalent influenza vaccine

“The study aims to evaluate the safety, immunogenicity and consistency of the immune response in vaccine batches”, informed Anvisa.

Today, the National Vaccination Program of the Ministry of Health uses the trivalent vaccine, composed of the fragmented and inactivated influenza virus, containing strain A (H1N1), strain A (H3N2) and strain B (Victoria and Yamagata lineage). 

The production process for the tetravalent vaccine, according to Anvisa, is similar to that of the trivalent vaccine, but has even greater protection against strains of the virus.

“It is expected to obtain a vaccine analogous to the trivalent, but with additional protection against a second B strain, determined seasonally by the World Health Organization. The addition of the second B strain of influenza (fourth strain in the vaccine) occurred in the transition from the bivalent seasonal vaccine to the trivalent, after the H1N1 influenza pandemic”, informed the agency.

(Source: Agência Brasil)

See also:

Alckmin vaccinates Lula at the launch of the National Vaccination Movement; see on Curto Flash

In a symbolic act, Vice President Geraldo Alckmin, who is a doctor, vaccinated President Lula with the bivalent vaccine against Covid-19. Find out more at Curto Flash, our selection of the main headlines of the moment. ⚡️